A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
18h agoen
From the article
Conditions : Intrahepatic Cholangiocarcinoma (Icc) Interventions : Drug: Gemcitabine; Drug: Cisplatin; Drug: Tislelizumab; Drug: Lenvatinib; Procedure: Transcatheter Arterial Chemoembolization; Procedure: Hepatic Arterial Infusion Chemotherapy Sponsors : Zhejiang Cancer Hospital Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
ClinicalKey
clinicalkey.com·1mo agoHong Jae Chon: Integrating Systemic Therapy in the Earlier Stages of Liver Cancer
OncoDaily·1d ago
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
ScienceDaily·14d ago
Early SBRT Before Chemoimmunotherapy Shows Promise in Borderline Resectable and Locally Advanced Pancreatic Cancer
OncoDaily·17m ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.